Evidence map›Paper›PMID 28854952›Full record

ArticleGenome medicine2017

Clinical implications of neoepitope landscapes for adult and pediatric cancers.

Yang-Yang Feng, Obi L Griffith, Malachi Griffith

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Yang-Yang FengMcDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA.
Obi L GriffithMcDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA. obigriffith@wustl.edu.
Malachi GriffithMcDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA. mgriffit@wustl.edu.

Funding

DEVELOPMENT OF INFORMATICS RESOURCES FOR INTERPRETATION OF CLINICALLY ACTIONABLE VARIANTS IN CANCERU01CA209936 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2016 to 2018
$1.0M
Integrated Analysis & Interpretation of Whole Genome Exome & Transcriptome SequenR00HG007940 · NHGRI · WASHINGTON UNIVERSITY · PI GRIFFITH, MALACHI · 2017 to 2019
$724k
DEFINING THE REGULATORY, NON-CODING, MUTATIONAL LANDSCAPE OF BREAST CANCERK22CA188163 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2014 to 2016
$515k
NCI NIH HHS K22 CA188163NCI NIH HHS U01 CA209936NHGRI NIH HHS R00 HG007940
6 · The paper itself

Abstract

Many immunotherapies rely on the presence of neoepitopes derived from somatic mutations that lead to altered peptide sequences. Several studies have now analyzed the neoepitope landscape of different cancer subtypes, predominantly for adult samples, which tend to feature significantly higher mutational burden. However, a new report publishing the first comprehensive analysis of the pediatric neoepitope landscape suggests that immunotherapies could also hold promise for pediatric cancers.See related research article 10.1186/s13073-017-0468-3.

Indexed as

ExomeNeoplasmsAdultChildDNA Mutational AnalysisGenome, HumanGenomicsHigh-Throughput Nucleotide SequencingHumansImmunotherapyMutationSequence Analysis, DNAExome sequencingImmunotherapyNeoepitopePersonalized cancer vaccineRNA sequencingWhole-genome sequencing

Identifiers

PMID28854952
PMCPMC5577778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.